Sarcoma patients also appeared to have diminished Th2 immune response, as evidenced by the expression of Th2-related genes GATA3, PTGDR2, and CCR3. Moreover, downregulation of the TOX gene suggests a possible role in modulating anticancer immune responses in sarcomas. The gene discussed is CCR3; the disease is sarcoma.